Key Opinion Leader Webinar on Pancreatic Cancer and Interim Phase 1/2 GOBLET Study Data to be held on November 14 at 10 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ONCY:
- Oncolytics to hold a key opinion leader webinar
- Oncolytics’ pelareorep shows 69% response rate in pancreatic cancer study
- Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
- Oncolytics reports Q3 EPS (8c), consensus (8c)
- Oncolytics reports interim results from Phase 1/2 GOBLET study